Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP6 | P51161 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9763711 | 0.85 | PKM (0.74) | FABP6POLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL14067207 | 0.84 | FABP6 (0.64) | FABP6POLBSMN1; SMN2KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1596692 | 0.83 | PKM (0.72) | FABP6POLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3323252 | 0.83 | KDM4E (0.65) | FABP6POLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL28121975 | 0.83 | FABP6 (0.67) | FABP6POLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL31329773 | 0.83 | FABP6 (0.67) | FABP6POLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL27943670 | 0.82 | MEN1 (0.64) | SMN1; SMN2KDM4EALDH1A1MAPK1MEN1 | |
| SCHEMBL10826072 | 0.81 | GAA (0.64) | FABP6POLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL18029395 | 0.81 | KDM4E (0.65) | FABP6POLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13149228 | 0.80 | CHRM2 (0.80) | FABP6SMN1; SMN2KDM4EALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | FABP6 3216/4885POLB 2640/4885SMN1; SMN2 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.